secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2026-08-21T20:30:28+00:00
Accession:  0001493152-26-039695
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma announces 1-for-7 reverse stock split effective Sept 1, 2026
--------------------------------------------------------------------------

- 1-for-7 reverse split effective Sep 1, 2026 at 12:01 a.m. ET; trading under KAPA with new CUSIP 48301N203.
- Every 7 shares reclassified to 1; no fractional shares, holders round up to nearest whole share.
- Proportional adjustments to warrants, convertible notes, and equity awards; authorized shares unchanged.
- Split intended to raise per-share price and maintain compliance with NYSE American listing requirements.
- VStock Transfer is exchange agent; holders in book-entry or street name need not take any action.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226039695/0001493152-26-039695-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315226039695/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-039695

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer